The effect of L-dopa on neuroleptic-induced catalepsy.
D000818:Animals; D002375:Catalepsy / Q000139:chemically induced; D002746:Chlorpromazine / Q000037:antagonists & inhibitors; D004295:Dihydroxyphenylalanine / Q000494:pharmacology*; D010134:Fenclonine / Q000037:antagonists & inhibitors; D005476:Fluphenazine / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009526:Nialamide / Q000037:antagonists & inhibitors; D010868:Pimozide / Q000037:antagonists & inhibitors; D051381:Rats; D013141:Spiro Compounds / Q000037:antagonists & inhibitors; D013997:Time Factors; D014149:Tranquilizing Agents / Q000037:antagonists & inhibitors*
D013141:Spiro Compounds; D014149:Tranquilizing Agents; D010868:Pimozide; D004295:Dihydroxyphenylalanine; D010134:Fenclonine; D005476:Fluphenazine; D009526:Nialamide; D002746:Chlorpromazine